会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 5. 发明授权
    • Aryl-cycloalkyl[b]pyrrole derivatives
    • 芳基 - 环烷基[b]吡咯衍生物
    • US4721725A
    • 1988-01-26
    • US823172
    • 1986-01-27
    • Scott A. BillerDonald S. Karanewsky
    • Scott A. BillerDonald S. Karanewsky
    • C07D209/18C07D209/52A61K31/40A61K31/405
    • C07D209/52C07D209/18
    • Aryl-cyclopenta- and arylcyclohexa[b]pyrrole derivatives are provided having the structure ##STR1## wherein n is 1 or 2; X is --OR.sup.1 or --NR.sup.2 R.sup.3 wherein R.sup.1 is H, lower alkyl, cycloalkyl, aryl, aralkyl or cycloalkylalkyl, and R.sup.2 and R.sup.3 may be the same or different and are H, lower alkyl, cycloalkyl, aryl, aralkyl or cycloalkylalkyl;Y is --OR.sup.4 or --NR.sup.5 R.sup.6 wherein R.sup.4 is H or lower alkyl, and R.sup.5 and R.sup.6 are the same or different and are H or lower alkyl; andZ is aryl.These compounds are useful in inhibiting the 5-lipoxygenation of arachadonic acid in RBL-1 cells and preventing leukotriene formation in macrophages and as such are useful as antiallergy agents and in treating inflammation and psoriasis.
    • 提供芳基环戊基和芳基环己基[b]吡咯衍生物,其具有结构,其中n为1或2; X是-OR1或-NR2R3,其中R1是H,低级烷基,环烷基,芳基,芳烷基或环烷基烷基,R2和R3可以相同或不同,是H,低级烷基,环烷基,芳基,芳烷基或环烷基烷基; Y为-OR4或-NR5R6,其中R4为H或低级烷基,R5和R6相同或不同,为H或低级烷基; Z是芳基。 这些化合物可用于抑制RBL-1细胞中花生四烯酸的5-脂氧合,并且可防止巨噬细胞中的白三烯形成,因此可用作抗过敏剂和治疗炎症和牛皮癣。
    • 6. 发明授权
    • Phosphorus-containing squalene synthetase inhibitors
    • 含磷的角鲨烯合成酶抑制剂
    • US5212164A
    • 1993-05-18
    • US501204
    • 1990-03-29
    • Scott A. BillerMichael J. Sofia
    • Scott A. BillerMichael J. Sofia
    • C07F9/38C07F9/40C07F9/44
    • C07F9/4469C07F9/3821C07F9/4012C07F9/4028C07F9/4037C07F9/4078
    • Compounds which are inhibitors of cholesterol biosynthesis (by inhibiting de novo squalene biosynthesis), and thus are useful as hypocholesterolemic agents and antiatherosclerotic agents are provided which have the structure ##STR1## wherein m is 0, 1, 2 or 3; n is 0, 1, 2, 3 or 4;Y.sup.1 and Y.sup.2 are H or halogen;R.sup.2, R.sup.3 and R.sup.4 may be the same or different and are independently H, metal ion, C.sub.1 to C.sub.8 alkyl or C.sub.3 to C.sub.12 alkenyl;X is O, S, NH or NCH.sub.2 R.sup.15 wherein R.sup.15 is H or C.sub.1 to C.sub.5 alkyl; andR.sup.1 is R.sup.5 --Q.sup.1 --Q.sup.2 --Q.sup.3 -- wherein R.sup.5, Q.sup.1, Q.sup.2 and Q.sup.3 are as defined herein;and when m is o, X is other than S; and if m is o and X is 0, then n is 1, 2, 3 or 4; including all stereoisomers thereof.
    • 作为胆固醇生物合成抑制剂的化合物(通过抑制从头角鲨烯生物合成),因此可用作具有下列结构的降血胆固醇药和抗动脉粥样硬化剂:其中m为0,1,2或3; n为0,1,2,3或4; Y1和Y2是H或卤素; R 2,R 3和R 4可以相同或不同,并且独立地为H,金属离子,C 1至C 8烷基或C 3至C 12链烯基; X是O,S,NH或NCH 2 R 15,其中R 15是H或C 1至C 5烷基; 并且R1是R5-Q1-Q2-Q3-,其中R5,Q1,Q2和Q3如本文所定义; 而当m为o时,X不为S; 如果m为o,X为0,则n为1,2,3或4; 包括其所有的立体异构体。
    • 9. 发明授权
    • Protein farnesyl transferase inhibitors
    • 蛋白法呢基转移酶抑制剂
    • US5523430A
    • 1996-06-04
    • US247743
    • 1994-05-23
    • Dinesh V. PatelScott A. BillerEric M. Gordon
    • Dinesh V. PatelScott A. BillerEric M. Gordon
    • C07C57/13C07C233/49C07F9/38C07C233/00
    • C07F9/3808C07C233/49C07C57/13C07F9/3826
    • Inhibition of farnesyl transferase, which is an enzyme involved in ras oncogene expression, and inhibition of cholesterol biosynthesis, are effected by compounds of the formula ##STR1## their enantiomers, diastereomers, and pharmaceutically acceptable salts, prodrugs, and solvates, wherein:X is --ONR.sup.1 C(O)--, --N(OR.sup.1)C(O)--, --NR.sup.1 C(O)--, --C(O)NR.sup.1 --, --NR.sup.1 S(O.sub.2)--, --C(O)O--, --OC(O)--, --O--, --NR.sup.1 -- or --(S)q;Y and Z are each independently --CO.sub.2 R.sup.2, --SO.sub.3 R.sup.2 or --P(O)(OR.sup.2)(OR.sup.3);R is alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkenylene or aryl;R.sup.1, R.sup.2 and R.sup.3 are each independently hydrogen, alkyl, aryl or aralkyl;m and n are each independently 0 or an integer from 1 to 5;p is 0 or 1; andq is an integer from 1 to 2.
    • 抑制参与ras癌基因表达的酶的法呢基转移酶和胆固醇生物合成的抑制由下式的化合物影响:它们的对映异构体,非对映异构体和药学上可接受的盐,前药和溶剂合物,其中:X是 (O) - , - N(OR 1)C(O) - , - NR 1 C(O) - , - C(O)NR 1 - , - NR 1 S(O 2) - , - (O) - , - O - , - NR 1 - 或 - (S)q; Y和Z各自独立地为-CO 2 R 2,-SO 3 R 2或-P(O)(OR 2)(OR 3); R是烷基,取代的烷基,烯基,取代的烯基,亚烯基或芳基; R1,R2和R3各自独立地为氢,烷基,芳基或芳烷基; m和n各自独立地为0或1至5的整数; p为0或1; q为1〜2的整数。